The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.
Terufumi Kato
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Takashi Seto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Makoto Nishio
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Koichi Goto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Shinji Atagi
Honoraria - Chugai Pharma
Yukio Hosomi
Honoraria - Chugai Pharma
Noboru Yamamoto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Toyoaki Hida
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Makoto Maemondo
Consultant or Advisory Role - AstraZeneca; Nippon Boehringer Ingelheim
Honoraria - Chugai Pharma
Research Funding - Nippon Boehringer Ingelheim
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Seisuke Nagase
No relevant relationships to disclose
Isamu Okamoto
Honoraria - Chugai Pharma
Takeharu Yamanaka
Honoraria - Chugai Pharma
Ryosuke Harada
Employment or Leadership Position - Chugai Pharma
Masahiro Fukuoka
Honoraria - Chugai Pharma
Nobuyuki Yamamoto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma